{
    "id": 10065,
    "fullName": "TMPRSS2 - ERG",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "TMPRSS2-ERG results from the fusion of TMPRSS2 and ERG, resulting in induced cell proliferation and increased cell invasion in culture and promotion of tumor growth in vivo (PMID: 18922926). TMPRSS2-ERG fusions have been identified in prostate cancer (PMID: 18922926).",
            "references": [
                {
                    "id": 3388,
                    "pubMedId": 18922926,
                    "title": "Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18922926"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 7113,
        "geneSymbol": "TMPRSS2",
        "terms": [
            "TMPRSS2",
            "PP9284",
            "PRSS10"
        ]
    },
    "variant": "TMPRSS2 - ERG",
    "createDate": "08/05/2015",
    "updateDate": "10/19/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 2078,
                "geneSymbol": "ERG",
                "terms": [
                    "ERG",
                    "erg-3",
                    "p55"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 2698,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lynparza (olaparib) induced DNA damage and inhibited invasion, metastasis, and growth of prostate cancer cells harboring the TMPRSS2-ERG fusion in culture and in cell line xenograft models (PMID: 21575865).",
            "molecularProfile": {
                "id": 10069,
                "profileName": "TMPRSS2 - ERG"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 3390,
                    "pubMedId": 21575865,
                    "title": "Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21575865"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20783,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lynparza (olaparib) did not inhibit proliferation of prostate cancer cell lines harboring TMPRSS2-ERG fusion in culture, only induced apoptosis through cytotoxic effects (PMID: 29465803).",
            "molecularProfile": {
                "id": 10069,
                "profileName": "TMPRSS2 - ERG"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 18040,
                    "pubMedId": 29465803,
                    "title": "Olaparib is effective in combination with, and as maintenance therapy after, first-line endocrine therapy in prostate cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29465803"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2701,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rubraca (rucaparib) induced senescence and increased radiosensitivity in prostate cancer cells harboring the TMPRSS2-ERG fusion in culture (PMID: 23565244).",
            "molecularProfile": {
                "id": 10069,
                "profileName": "TMPRSS2 - ERG"
            },
            "therapy": {
                "id": 6652,
                "therapyName": "Radiotherapy + Rucaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3425,
                    "pubMedId": 23565244,
                    "title": "PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23565244"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5474,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, YK-4-279 inhibited invasion of a prostate cancer cell line harboring TMPRSS2-ERG in culture (PMID: 21559405).",
            "molecularProfile": {
                "id": 10069,
                "profileName": "TMPRSS2 - ERG"
            },
            "therapy": {
                "id": 3419,
                "therapyName": "YK-4-279",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4357,
                    "pubMedId": 21559405,
                    "title": "YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21559405"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2699,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lynparza (olaparib) and Temodar (temozolomide) inhibited tumor growth of prostate cancer cells harboring the TMPRSS2-ERG fusion in cell line xenograft models (PMID: 21575865).",
            "molecularProfile": {
                "id": 10069,
                "profileName": "TMPRSS2 - ERG"
            },
            "therapy": {
                "id": 1438,
                "therapyName": "Olaparib + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3390,
                    "pubMedId": 21575865,
                    "title": "Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21575865"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11669,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MK-0752 reduced migration of a prostate cancer cell line harboring TMPRSS2-ERG in culture (PMID: 28783165).",
            "molecularProfile": {
                "id": 10069,
                "profileName": "TMPRSS2 - ERG"
            },
            "therapy": {
                "id": 815,
                "therapyName": "MK0752",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9696,
                    "pubMedId": 28783165,
                    "title": "TMPRSS2-ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783165"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20764,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xtandi (enzalutamide) treatment resulted in greater inhibition of AR signaling, androgen biosynthesis genes expression, and proliferation in prostate cancer cells harboring TMPRSS2-ERG compared to ERG knockdown cells in culture, and significantly reduced tumor burden in an intratibial xenograft model (PMID: 31638934).",
            "molecularProfile": {
                "id": 35331,
                "profileName": "TMPRSS2 - ERG AR pos"
            },
            "therapy": {
                "id": 1262,
                "therapyName": "Enzalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18033,
                    "pubMedId": 31638934,
                    "title": "TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31638934"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20779,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpressing TMPRSS2-ERG in AR-negative prostate cancer cells did not confer sensitivity to Lynparza (olaparib) in cell culture (PMID: 29465803).",
            "molecularProfile": {
                "id": 35332,
                "profileName": "TMPRSS2 - ERG AR neg"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 18040,
                    "pubMedId": 29465803,
                    "title": "Olaparib is effective in combination with, and as maintenance therapy after, first-line endocrine therapy in prostate cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29465803"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 10069,
            "profileName": "TMPRSS2 - ERG",
            "profileTreatmentApproaches": [
                {
                    "id": 6355,
                    "name": "PARP Inhibitor (Pan)",
                    "profileName": "TMPRSS2 - ERG"
                },
                {
                    "id": 6354,
                    "name": "PARP-1 Inhibitor",
                    "profileName": "TMPRSS2 - ERG"
                }
            ]
        },
        {
            "id": 35331,
            "profileName": "TMPRSS2 - ERG AR pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35332,
            "profileName": "TMPRSS2 - ERG AR neg",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}